Ayush export declines by 7.4% in first nine months of FY 26

New Delhi:  Exports of Ayush and herbal products have reported a decline of 7.42% during the first nine months of the fiscal year 2025-26, compared to the same period of previous fiscal year.

Exports during the quarter from October to December, 2025 registered a decline of 16.14%, while for the month of December, the exports declined almost 10.2%, on a Year-over-Year (YoY) basis.

During the period of April to December, 2025, exports of Ayush and herbal products stood at $471.67 million compared to $509.49 million during the corresponding period of previous fiscal year. Quantity of exports declined 1.29% to 91,493 MT during the period compared to 92,685 MT a year ago.

During the third quarter of the fiscal year, ending December 31, 2025, exports stood at $137.66 million, as against $164.15 million during the same period a year ago. Quantity witnessed a decline of almost 6% to 29,653 MT compared to 31,502 MT registered in the same quarter a year ago.

Exports during the month of December, 2025, was at $52.15 million, as compared to $58.05 million in the same month of previous fiscal year. Quantity declined 1.5% to 12,315 MT, as against 12,133.6 MT reported during December, 2024.

In Rupee terms, exports of Ayush and herbal products declined 3.78% at Rs. 4,111.5 crore during the first nine months of the fiscal year, compared to Rs. 4,272.93 crore during the same period of last year. Exports during the quarter ended December reported a 11.45% decline at Rs. 1,227.6 crore on a YoY basis as against Rs. 1,386.4 crore last year.

During the month of December, exports declined 4.8% in rupee terms, at Rs. 469.8 crore as against Rs. 493.38 crore during the same month of last year.

As reported earlier, the exports of Ayush and herbal products have reported a decline of 3.3% during the first half of the fiscal year 2025-26, at $334.01 million compared to $345.33 million during the corresponding period of previous fiscal year. Quantity of exports, however, grew 1.13% to 61,879 MT during the period.

Exports during the first quarter of the current fiscal, ended June 30, 2025 reported a marginal growth of 6% and stood at $175.7 million, as against $174.8 million during the three months from April to June, 2024.

Ayush and herbal products exports reported a growth of 3.6 per cent during the fiscal year 2023-24, at $651.17 million as compared to the same period of previous year. During 2022-23, the exports were $628.54 million. The year 2022-23 registered a growth of 2.68 per cent in exports, from $612.12 million in the previous year.

The Ministry of Ayush has established Ayush Export Promotion Council (Ayushexcil) to promote Ayush products and services globally by the Ministry of Ayush and supported by the Union ministry of commerce. It was officially launched at Global Ayush Investment and Innovation Summit held in Gandhinagar, Gujarat on April 20, 2022, and aimed to oversee exports of products of Ayurveda, Homoeopathy, Siddha, Sowa/Rigpa and Unani systems and address trade issues pertaining to these sectors.

Related Posts

Rajasthan Bans 7 Sub-Standard Medicines

Prioritising public health and patient safety, the Commissionerate of Food Safety and Drug Control, Rajasthan, has issued an alert regarding seven medicines and declared them “Not of Standard Quality”. Prioritising…

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

NCB Hyderabad raids illegal lab, seizes 69 kg of Alprazolam worth Rs 17.4 crore

Rajasthan Bans 7 Sub-Standard Medicines

Rajasthan Bans 7 Sub-Standard Medicines

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Obesity drug market to gain as Indians pop the pill and Chinese bring more

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23